Advertisement
Canada markets closed

  • S&P/TSX

    21,708.44
    +52.39 (+0.24%)
     

  • S&P 500

    5,011.12
    -11.09 (-0.22%)
     

  • DOW

    37,775.38
    +22.07 (+0.06%)
     

  • CAD/USD

    0.7256
    -0.0007 (-0.10%)
     

  • CRUDE OIL

    84.60
    +1.87 (+2.26%)
     

  • Bitcoin CAD

    85,048.84
    -411.03 (-0.48%)
     

  • CMC Crypto 200

    1,278.38
    +392.84 (+42.77%)
     

  • GOLD FUTURES

    2,404.10
    +6.10 (+0.25%)
     

  • RUSSELL 2000

    1,942.96
    -4.99 (-0.26%)
     

  • 10-Yr Bond

    4.6470
    +0.0620 (+1.35%)
     

  • NASDAQ futures

    17,319.50
    -227.75 (-1.30%)
     

  • VOLATILITY

    18.00
    -0.21 (-1.15%)
     

  • FTSE

    7,877.05
    +29.06 (+0.37%)
     

  • NIKKEI 225

    37,097.54
    -982.16 (-2.58%)
     

  • CAD/EUR

    0.6820
    -0.0001 (-0.01%)
     

Ultimovacs ASA: Invitation to Third quarter 2022 results webcast presentation

Ultimovacs ASA
·1 min read
Ultimovacs ASA
Ultimovacs ASA

Oslo, 3 November 2022: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical stage leader in immune stimulatory vaccines for cancer, invites to a webcast presentation of its third quarter 2022 results on Thursday 10 November 2022.

The presentation can be followed as a live webcast accessed through a link on www.ultimovacs.com at 14:00 CET on Thursday 10 November 2022. The webcast presentation will be available on the Ultimovacs website, and it will be possible to post questions during the presentation through the webcast.

The report and presentation will be available on the company website from 08:00 CET the same day.

ADVERTISEMENT

For further information, please see www.ultimovacs.com or contact:

Carlos de Sousa, CEO
Email: carlos.desousa@ultimovacs.com
Phone: +47 908 92507

Hans Vassgård Eid, CFO
Email: hans.eid@ultimovacs.com
Phone: +47 482 48632

Anne Worsøe, Head of IR & Communication
Email: anne.worsoe@ultimovacs.com
Phone: +47 906 86815